US 11,685,898 B2
Cartilage-derived mesenchymal cell lines
Qian Chen, Barrington, RI (US); and Chathuraka T. Jayasuriya, Barrington, RI (US)
Assigned to RHODE ISLAND HOSPITAL, Providence, RI (US)
Appl. No. 16/81,029
Filed by Rhode Island Hospital, Providence, RI (US)
PCT Filed Feb. 28, 2017, PCT No. PCT/US2017/019991
§ 371(c)(1), (2) Date Aug. 29, 2018,
PCT Pub. No. WO2017/151646, PCT Pub. Date Sep. 8, 2017.
Claims priority of provisional application 62/301,600, filed on Feb. 29, 2016.
Prior Publication US 2021/0198630 A1, Jul. 1, 2021
Int. Cl. C12N 5/071 (2010.01); C12N 5/077 (2010.01); A61P 19/04 (2006.01); A61K 35/32 (2015.01); C12N 15/86 (2006.01); G01N 33/50 (2006.01)
CPC C12N 5/0655 (2013.01) [A61K 35/32 (2013.01); A61P 19/04 (2018.01); C12N 15/86 (2013.01); G01N 33/5044 (2013.01); C12N 2740/10043 (2013.01)] 2 Claims
 
1. A stable human chondroprogenitor cell line or stable human osteochondroprogenitor cell line that expresses at least five times less lubricin (PRG4) relative to chondrocytes derived from healthy adult tissue, wherein:
(a) the cell line expresses at least three times less matrilin 3 (MATN3) relative to chondrocytes derived from healthy adult tissue,
(b) the cell line expresses two times less type I collagen (COL1) relative to bone marrow-derived mesenchymal stem cells (BM-MSCs);
(c) the cell line expresses the mesenchymal cell surface markers CD29, CD49c, CD105, and CD166;
(d) the cell line does not express the bone marrow-derived mesenchymal stem cell surface marker SSEA4; and
(e) the cell line expresses the chondrocyte cell surface marker CD54.